Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 CHF of revenue, 9.3 CHF is left as net profit.
- It earns 8.7 CHF a year on every 100 CHF of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 5.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 27.2 CHF for 1 CHF of yearly profit. Over the last five years it was 36.7 CHF on average.
Valuation in detailIs it growing?
SlowlyRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 7.3% a year over 5 years. Over the last 3 years it grew by 2.2% a year. For the next fiscal year analysts expect revenue to grow by 0.2%. Earnings per share fell by 5.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CHF of revenue goes
- Cost of sales 57 CHF
- Sales and administration 30 CHF
- Taxes and other 4.4 CHF
- Net profit 9.3 CHF
Net profit, industry median (Chemicals - Specialty) 6.0 CHF
Out of every 100 CHF of revenue, 9.3 CHF is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.92%
- Paid out of profit
- 52%
The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.